United Therapeutics Remodulin Decision Expected Soon After Cmte. Review
Executive Summary
FDA action on United Therapeutics' NDA for Remodulin in the treatment of pulmonary arterial hypertension therapy is expected soon after an Aug. 9 review by FDA's Cardiovascular & Renal Drugs Advisory Committee.
You may also be interested in...
Genentech, FDA Discussing Herceptin Label Changes To Reflect New PK Data
Genentech and FDA are discussing updates to Herceptin labeling following the submission of preliminary data suggesting the half-life of trastuzumab is up to five times longer than previously thought.
United Therapeutics Remodulin
FDA's Cardiovascular & Renal Drugs Advisory Committee will review the Remodulin NDA (21-272) for treatment of pulmonary hypertension during the morning of Aug. 9. The firm anticipates action on the application shortly following the meeting (1"The Pink Sheet" July 2, p. 18)
Genentech, FDA Discussing Herceptin Label Changes To Reflect New PK Data
Genentech and FDA are discussing updates to Herceptin labeling following the submission of preliminary data suggesting the half-life of trastuzumab is up to five times longer than previously thought.